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ABSTRACT OF THE THESIS 
 
 
Comparative Effectiveness Research of Dentin Hypersensitivity Intervention - A Mixed 
Systematic Review Analysis 
 
by 
 
Nouf Abduallah A Alaskar 
 
Master of Science in Oral Biology 
University of California, Los Angeles, 2016 
Professor Francesco Chiappelli, Chair 
 
 
Introduction and Objective: Dentin Hypersensitivity (DH) is one of the common oral 
conditions that affect adult population and defined as a short, sharp pain arising from exposed 
dentin in response to stimuli typically thermal, evaporative, tactile, osmotic or chemical and 
cannot ascribe to any other form of dental pathology or disease. DH development through two 
distinct but interrelated phases of tooth wear and gingival recession associated with different 
etiological factors. 
Morphological alterations in DH and intradental nerve excitability are the underlying sources 
that lead to disease progression, pain evocation as well as therapeutic strategies investigations to 
iii		
interrupt pain transmission. Numerous treatment modalities have been used to manage DH. The 
interventions of DH have been classified based on the mode of delivery  (in-office or 
professionally-applied therapy and over-the-counter (OTC) or at- home therapy). The other 
classification used based on the mechanism of action and could be divided into two main 
categories: the dentinal tubules occluding agents to block the hydrodynamic mechanism of pain 
stimulation and the nerve desensitizers to interrupt the neural response to pain stimuli (neural 
blocker). The main objective for any dentine-desensitizing agent is to produce a clinically 
significant reduction in clinical symptoms and minimize or abolish the symptoms of pain or 
discomfort associated with DH. The variety of products and techniques used for the treatment of 
DH indicated a doubt among dentists about the best treatment option, as well as dissatisfaction 
with outcomes of available treatments, which necessitate the conduction of a comparative 
effectiveness research and a practice analysis to provide dentists and patients with precise 
scientific information for comparing the effectiveness and safety of alternative treatment options 
in resolving DH among different available treatment. The aim of the study is to conduct a 
comparative effectiveness research to find out if In-office desensitizing agents with dentinal 
tubules occlusion mechanism of action are more effective than self-applied desensitizing 
toothpaste with a neural stimulus blocker mechanism of action in resolving dentin 
hypersensitivity. 
Methods: Search for systematic reviews, randomized clinical trials and observational studies 
were done using the National Library of Medicine-PubMed, Cochrane’s library and the 
American Dental Association (ADA) web Library. The relevance of the identified systematic 
reviews, clinical trials and observational studies to the study and PICOTS question was assessed 
using the inclusion and exclusion criteria. The quality of evidence and clinical relevance analysis 
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achieved using validated and reliable instruments by two independent readers, and all 
disagreements resolved by discussion after establishing the inter-rater reliability of the two 
readers. The revised Assessment of Multiple Systematic Reviews (R-AMSTAR) instrument 
utilized to assess and quantify the quality of retained systematic reviews, the quantified Risk of 
Bias instrument utilized to evaluate the quality of retained clinical trials and the Expansion in the 
Grading of Recommendations Assessment, Development and Evaluation (Ex-GRADE) was used 
to evaluate the clinical relevance and the strength of recommendation. Acceptable sampling 
analysis was done using the Friedman test statistics. Meta-analysis was done on the two highest 
quality and homogenous clinical trials.  
Results: Three out of six systematic reviews were considered as high-quality studies and two out 
of thirty-one clinical trials were considered as high-quality studies. However, the bibliome was 
concerned with a body of literature that has a considerable heterogeneity in terms of quality of 
the evidence, which prevented further work toward establishing the quantitative and qualitative 
consensus of the best evidence. Therefore, an alternative approach for acceptable sampling was 
conducted. Whereby the top 20% highest scoring papers in the bibliome were accepted. So, out 
of thirty-one studies, seven studies included and considered as high quality studies. The results of 
the qualitative analysis of this review shows that 5% potassium nitrate toothpaste has inferior 
effectiveness in DH management as at home intervention, however, the reduction in the 
hypersensitivity increase with each recall that suggests the slow effectiveness that could be 
explained by the requisite of maintaining a high level of potassium nitrate to reach the maximum 
effectiveness.  5% potassium was not effective compared to in-office desensitizing intervention. 
Although it is difficult to prove or reach a conclusive evidence of the best treatment option, 
treatment approaches with resin-based composite restoration and glass ionomer liner resulted in 
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statistically significant reduction in sensitivity. Yet, the complicated procedure of application of 
these restorations might be considered in terms of time and cost in treating dentin 
hypersensitivity. Furthermore, it considered as technique sensitive owing to the tendency to 
perform an overhang at the gingival margins, which contribute to the development of gingivitis 
or jeopardize the biological width of the periodontal tissues. Gluma and fluoride varnishes were 
effective in reducing DH for up to 6 months with no reported adverse effects aside to the time 
and cost consideration.  
Conclusion: Based on the qualitative analysis of this review, the 5% potassium nitrate toothpaste 
has inferior effectiveness in DH management as at home intervention, which was not effective 
compared to in-office desensitizing interventions. Resin-based composite restoration and glass 
ionomer liner as in-office interventions yielded statistically significant reduction in sensitivity. 
However, the complicated procedure of application of these restorations might be considered in 
terms of time and cost in treating dentin hypersensitivity, which suggest that Gluma and fluoride 
varnishes might be superior treatment options in reducing DH in terms of efficacy and 
effectiveness. This review highlights the extent of heterogeneity and quality inferiority of clinical 
trials in this field, which impact the degree of their reliability. Also, it necessitates the future 
conduction of well-constructed clinical trials that directed to overcome current deficiencies and 
weaknesses. 
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Chapter 1 
Introduction 
 
1. Dentin Hypersensitivity 
 
1.1.   Definition of Dentin Hypersensitivity: 
Dentin hypersensitivity (DH) defined as a short, sharp pain arising from exposed dentin in 
response to stimuli typically thermal, evaporative, tactile, osmotic or chemical and cannot 
ascribe to any other form of dental pathology or disease as proposed by Holland and later by the 
Canadian Advisory Board on Dentin Hypersensitivity (Holland et al. 1997, Canadian Advisory 
Board on Dentine Hypersensitivity 2003) 
The term hypersensitive dentin is widely used, however patients recognize exposed dentin as 
hypersensitive due to the lack of sensation before dentin exposure (Addy 2015). Dentin is an 
innervated tissue that protected by enamel or cementum. Therefore, losing these protective layers 
will cause the feeling of sensitivity. Though, the term ‘Dentin Hypersensitivity’ (DH) was used 
within the literature to describe that condition. 
 
1.2.    Prevalence of Dentin Hypersensitivity: 
Dentin Hypersensitivity (DH) is one of the common oral conditions that affect adult population. 
Mostly, patients with DH range from 20 to 40 years and the peak in incidence is in the late 
thirties (Rees et al 2000). The prevalence of dentine hypersensitivity conflictingly ranges from 
1.34% (Bamise et al. 2007) to 98% (Chabanski et al 2012). This conflicting can be explained by 
the selection criteria used for different study samples, whether the source of data is based on 
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clinical evaluation or patient-based questionnaires and especially by the selected diagnostic 
approaches as DH diagnosed by exclusion (West et al. 2014, Gernhardt et al. 2012). Relatively 
some studies have reported a high incidence of DH among females (Rees et al. 2004, Taani and 
Awartani, 2002). This could reflect their better oral hygiene awareness and their dietary habits. 
Furthermore, females also tend to visit the dental clinic more often, which may result in an over-
representation and, therefore, introduce a selection bias in studies samples. In addition, females 
eventually have more concerns about health problems than males, which may introduce a 
detection bias for females (Taha 2015). 
DH affects the quality of life of patients as a consequence of frequent pain and discomfort, which 
in turn cause behavior modification. Such as restricted dietary selection, avoiding chilled food 
and drink or prevent optimum oral hygiene that negatively affect the oral health (Boiko et al. 
2010). 
1.3.   Mechanism of Dentine Hypersensitivity: 
Dentine is a vital tissue that acquires the ability to react to physiological and pathological stimuli 
(Addy et al. 2000). Histologically, odontoblasts that are the principal elements of dentine tissue 
located along the dentin-pulp border and comprise the outermost region of the pulp.  It plays an 
important role in dentin formation. It composed of odontoblasts cell bodies and odontoblastic 
processes that extend within the dentinal tubules, which filled by dentinal fluid emerging from 
the blood vessels of the pulp (Thomas et al. 1979) 
To explain the mechanism of DH pain the literature discusses three main theories that have been 
proposed to explain the mechanism of DH, these are the direct nerve stimulation theory, the 
odontoblast-receptor theory, and the hydrodynamic theory (Addy et al. 2000). DH has mainly 
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explained by the hydrodynamic theory. Which first hypothesized by Gysi as a fluid flow 
movement outward from the pulp along dentine tubules (West et al.2012). Then Brannstrom was 
able to approve it by studying the fluid movement in dentine in response to thermal, evaporative, 
tactile, and osmotic stimuli (Brännström et al.1962, 1966, 1967,1968,1992) 
Basically, DH pain is stimulus-based pain that induced fluid flow in the dentinal tubules and 
consequently, alters the pressure, which activates the mechanoreceptor response located in A-
beta and A-delta nerve fibers and the pulp-dentine border area. A-beta and some A-delta fibers 
are Intradental myelinated nerve that responds to stimuli by alteration of the fluid flow in the 
dentinal tubules, resulting in prominent short, sharp pain of DH (Narhi et al. 1992) 
Microscopically, different studies showed the features that positively correlate with the degree of 
hypersensitivity (Brännström.1965, Yoshiyama et al. 1996). These features include the patency 
of the dentinal tubules, density, diameter and size of the open dentinal tubules. In sensitive teeth, 
the number of tubules per unit area is about eight times greater than the number found in non-
sensitive teeth, and the tubular diameter is two times greater (Absi et al 1987). Furthermore, 
according to the hydrodynamic theory of dentin sensitivity, the amount of fluid flow in 
hypersensitive teeth should be greater than the flow in the non-sensitive teeth in response to 
stimuli (Absi et al 1987).  The association of wider diameter of dentinal tubules with sensitive 
teeth has been explored compared to the non-sensitive teeth. As the flow through a capillary 
follows the Poiseuille’s law, which states that the rate of movement is dependent on the radius of 
the capillary to the power four. Thus, doubling the dentinal tubule radius would increase the flow 
16 times (Absi et al 1987). Additionally, Pulpal inflammation could be responsible for increasing 
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pain intensity and decreasing the pain threshold, thus exposed dentin become hypersensitive 
(Pashley, 2013). 
1.4.   Etiology and Predisposing Factors: 
In order to develop DH, dentin must undergo two different phases. Initially, dentine exposure 
phase that occurred by the loss of enamel or cementum with gingival recession, which called 
(lesion localization phase). Next, the patent or un-occluded dentinal tubules that connect the pulp 
to the oral environment, which called the (lesion initiation phase). Thus, not all exposed dentin is 
sensitive but it has to undergo the initiation phase (Addy. 2002). Lesion initiation and dentinal 
tubules’ patency could be due to the absence of the transient smear layer, which represents the 
protein and inorganic debris derived from saliva and oral environment. Additionally, the degree 
of dentin sclerosis and the extent of occlusion by reparative dentine (secondary dentin lay down) 
on the pulpal surface could play an important role in the fluid movement within the dentine 
tubules (Yoshiyama et al. 1996).     
Basically, DH development is through these two distinct but interrelated phases associated with 
different etiological factors such as tooth wear and gingival recession (Olley and Bartlett 2015).  
Gingival recession and migration apical to the cemento-enamel junction as well as cementum 
loss are highly contributed to dentinal tubules exposure and DH development  (Smith. 1997). 
Gingival recession result from multiple factors such as the anatomy of the buccal plate of the 
alveolar bone (dehiscence and fenestration) or high frenal attachment, tooth anatomy, soft-tissue 
trauma as a result of vigorous tooth brushing or orthodontic movement, all can prompt the 
gingival recession. Another indirect cause of the gingival recession is the poor oral hygiene, 
leading to periodontal disease (Smith. 1997). 
Physiologically, teeth wear considered as a normal process that advances with aging and allow 
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extended time for the pulp to develop a protective layer of reparative dentine. Thus, will block 
the fluid flow within the dentinal tubules, which explain the absence of DH in that situation 
(Krauser.1986). In contrast, teeth wear seen in young patients with fast progression rate will be 
considered as pathological teeth wear. As reported, it is associated with DH symptoms, since it 
leaves the dentinal tubules exposed and patent (Smith and Knight 1984). The process of teeth 
wear and enamel loss is an irreversible loss of dental hard tissue caused by multifactorial 
etiology that could be subdivided into attrition, abfraction, abrasion and erosion (Bartlett and 
Smith 2000). 
Attrition is the wear that occurs when teeth are in direct contact and grind against each other, 
usually associated with the occlusal function. Excessive or parafunctional habits, such as 
bruxism, may result in extreme pathologic wear and increased sensitivity (Meurman and Sovari 
2000). 
Abrasion is the tooth wear caused by objects other than other teeth. Such as, tooth brushing 
including the type of toothbrush, brushing technique and toothpaste also considered as a potential 
abrasive factor (West et al. 1998). Moreover, its combination with other factors such as, erosion 
will accelerate the process of tooth wear. Actually, erosion and acid exposure play the main role 
of tooth wear as well as DH localization and initiation (Absi et al. 1992, West et al. 2014). 
Whereby the superficial demineralization of hard tissue and the chemical dissolution of the 
apatite crystals in enamel by the acid attack will result in tissue loss and tubular opening (Absi et 
al. 1992). Typical sources of intrinsic acid are the stomach acid containing hydrochloric acid 
(HCL) due to vomiting or gastro-esophageal reflux (Scheutzel 1996). While the typical extrinsic 
sources could be the dietary consumption of acidic food or beverages such as acidic citrus and 
other fruits, carbonated beverages, beers, herbal teas, vinegar and pickles, candies, or acidic 
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medication. Also, acidic exposure associated with some occupational environment (Lussi. 2006). 
Furthermore, Abfraction lesions, which developed near the cervical margin as a result of occlusal 
stress. Usually, it evolves the non-carious cervical lesions (NCCLs) and associated with DH 
(Addy. 2002). Generally, Abrasion and erosion are the most common etiological factors to 
develop dentin hypersensitivity. Also, It is considered that gingival recession is the predominant 
localization factor and erosion is the predominant initiation factor. While DH is frequently seen 
in patients with periodontitis, transient hypersensitivity may occur after periodontal procedures 
such as deep scaling, root planning or gingival surgery. Transient hypersensitivity also may be 
associated with teeth whitening and restorative procedures (Orchardson et al. 2006) 
 
1.5.  Diagnosis and Assessment Methods: 
 
The diagnosis of dentine hypersensitivity (DH) is not an easy direct process since the pain and 
clinical signs of the condition are similar to other oral conditions associated with pain that are 
managed and treated differently, besides the absence of a decisive test for DH. Therefore, an 
acceptable diagnosis of DH will be possible using the differential diagnostic approach and the 
elimination of all dental and periodontal conditions with the same pain perception (Holland et al. 
1997, Addy. 2000)  
Synchronically, it is essential to obtain a comprehensive medical history and dental history, in 
particular, pain history alongside the presence of certain clinical features or patient’s habits. For 
instance, the exposed dentine as a result of gingival recession or enamel wear, high acidic diet, 
smoking and excessive brushing, are associated with DH, and their presence or history might 
suggest that DH is the cause of the pain reported. Additionally, Patients with xerostomia are 
potentially at a higher risk of erosion leading to DH (West et al. 2012).  
According to the Canadian Advisory Board on Dentin Hypersensitivity, the dental professional is 
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advised to follow six steps with patients suffering from hypersensitivity teeth: (Canadian 
Advisory Board on Dentine Hypersensitivity 2003) 
• Diagnosis of DH, comprising a patient’s history and a brief clinical examination. 
• Identification of etiologic and predisposing factors, particularly dietary and oral hygiene 
habits associated with erosion and abrasion. 
• Differential diagnosis, to exclude all other dental conditions with alike pain symptoms. 
• If present, treatment of all conditions with symptoms similar to dentin hypersensitivity. 
• Elimination of etiologic and predisposing factors through dietary advice and improved 
oral hygiene instruction. 
• Recommendation or implementation of treatment based on individual needs. 
 
Assessing DH and its severity are achieved by two different assessment methods. Stimulating the 
teeth with stimuli known to provoke a hypersensitivity response and evaluate the stimulus 
intensity (stimulus-based assessment). Such stimulation will cause the pain, and this must be 
taken into account when interpreting a patient’s response as a pain threshold measurement. 
(Gillam et al. 1997, Holland et al. 1997, Gernhardt 2012) 
The other method is to assess the pain severity following the application of a standardized 
stimulus (response-based assessment). It is a subjective evaluation of pain produced by a defined 
stimulus such as tactile, cold, and evaporative air stimuli. After the stimulation patient’s response 
can be quantified by using a validated pain scale. Commonly used scale is the visual analog scale 
(VAS) in which the patient places a mark on a 100-mm line labeled from no pain to worst pain 
(Holland et al. 1997, Gernhardt 2012). Another method of quantification is to use a verbal 
descriptor scale, which uses word descriptors as a scaling technique to describe variations in pain 
according to the patient’s spontaneous report or by the use of a validated questionnaire. 
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Furthermore, another scale has been used called the Schiff cold air sensitivity scale. This scale is 
scored as follows: (Schiff et al. 2009) 
• 0 Subject does not respond to air stimulus  
• 1 Subject responds to air stimulus but does not request discontinuation of stimulus. 
• 2 Subject responds to air stimulus and requests discontinuation or moves from the 
stimulus. 
• 3 Subject responds to air stimulus, considers stimulus to be painful and requests 
discontinuation of the stimulus. 
Clinically, it is recommended to confirm DH diagnosis with at least two different hydrodynamic 
stimuli (Canadian Advisory Board on Dentine Hypersensitivity 2003). 
 
1.6.  Dentin Hypersensitivity Treatment: 
Morphological alterations in DH and intradental nerve excitability are the underlying sources 
that lead to disease progression, pain evocation as well as therapeutic strategies investigation to 
interrupt pain transmission. Numerous treatment modalities have been used to manage DH. The 
management of DH has been classified based on the mode of delivery  (in-office or 
professionally-applied therapy and over-the-counter (OTC) or at- home therapy). OTC 
desensitizing agents are generally based on formulations with the same active ingredients as the 
in-office agents, yet with a lower concentration to allow safe usage and tend to be inexpensive 
and can treat simultaneously generalized DH affecting many teeth (Orchardson et al. 2006). The 
other classification used based on the mechanism of action and could be divided into two main 
categories: the dentinal tubules occluding agents to block the hydrodynamic mechanism of pain 
stimulation and the nerve desensitizers to interrupt the neural response to pain stimuli (neural 
blocker) (Orchardson et al. 2006). As the foremost objective for any dentine-desensitizing agent 
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is to produce a clinically significant reduction in clinical symptoms and minimize or abolish the 
symptoms of pain or discomfort associated with DH, it is very important to start with patient 
counseling and education about the dietary habits, oral hygiene instruction and subsequent 
monitoring the condition over time as the first line of treatment in order to eliminate any 
etiological and predisposing factors (Canadian Advisory Board on Dentine Hypersensitivity 
2003). Afterward, different treatment approaches could be prescribed based on the clinical 
situation, and the clinician experience. Multiple systematic reviews have been published on 
different treatment modalities with a different mechanism of action and mode of delivery in 
order to assess the evidence that support the available treatment options. 
 
1.6.1.  Nerve Desensitization (Neural Blocker) 
Potassium salts containing kinds of toothpaste are the most widely used at-home treatment for 
DH (Orchardson et al. 1987). Potassium ions have been shown to interrupt the neural response to 
pain stimuli by diffusing along the tubules and raising the concentration of local extracellular 
potassium ions, thus blocking intradental nerve function. Accordingly, It is important to maintain 
the high level of extracellular potassium ions to have the desired effect, which may take longer 
time (Nähri et al. 1992). Potassium-containing products (nitrate, chlorine and citrate) including 
both toothpaste and mouthrinse formulations have been reported to be effective in reducing DH 
compared to placebo controls (Orchardson and Gillam 2000, Markowitz 2009). The 5 % 
potassium nitrate formulations have been the most extensively evaluated desensitizing agent 
(Rösing et al. 2009). Sensodyne toothpaste that contains 5% Potassium nitrate as an active 
ingredient has been accepted by the ADA Council on Scientific Affairs to receive the ADA seal 
as the only approved OTC desensitizing agent. Though, previous systematic review directed to 
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assess the effectiveness of potassium-containing toothpaste in reducing DH by including 
randomized control trials (RCTs) comparing potassium to non-potassium containing toothpaste 
which, failed to show a significant effect (Poulsen et al. 2006). 
 
1.6.2.  Dentinal Tubule Occluding Agents 
The most direct approach to desensitize dentine is the alteration of fluid flow in dentinal tubules 
by dentinal tubules occlusion. The effectiveness of the tubular occluding agents will depend on 
their resistance to removal, especially in an acidic environment. There are multiple and complex 
techniques in which different agents and products could potentially work to partially or 
completely occlude tubules (Markowitz 2009, Cummins 2010) 
• Deposition of a thin-film coating layer by creating an artificial smear layer over the open 
tubules. 
Typically, the polymer-based materials such as adhesive materials, restorative resins, dentin 
bonding agents or Glass ionomer cement, have been proposed to work by that mechanism of 
tubular occlusion. Several investigators have reported the application of dentin adhesive 
materials for relieving DH (Mehta et al. 2014, Brunton et al. 2000). Basically, it promotes a 
micro-mechanical interlocking through a hybridization process. Besides the presence of 
functional monomers, they have the potential to interact chemically with the calcium ions from 
the residual hydroxyapatite that remains available within the submicron hybrid layer (Pei et al. 
2013). 
• Induction of protein precipitation 
The Glutaraldehyde - based desensitizing materials aside to hydroxyethyl methacrylate will 
occlude the dentinal tubules by interaction with the dentinal proteins. It reacts with the serum 
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albumin in the dentinal fluid, resulting in precipitation of the serum albumin.  This reaction also 
causes the polymerization of 2- hydroxyethyl methacrylate (HEMA) that block the dentinal 
tubules (Stewardson et al. 2004, Qin et al. 2006). Several investigators have reported the 
effectiveness of protein precipitation to reduce DH (Duran et al. 2005, Schmidin and Sahrmann 
2012). 
• Deposition of a layer of fine particles (physical barrier) 
Several desensitizing materials have used this technique to create a physical barrier on the 
exposed dentinal tubules. It distributed directly as fine abrasive particles or formed as a 
precipitate in situ, such as strontium, stannous fluoride, and calcium phosphate particles 
(Cummins 2010). Strontium has been investigated as a treatment for DH since 1956. It 
introduced as 25% strontium/water solution and a 75% glycerin paste (Pawlowska 1956, West 
2008). Many investigations reported their effectiveness in treating DH compared to placebo 
controls (Kobler et al 2008). The main mode of action of strontium formulations was considered 
to be one of the tubular occlusion through the participation of strontium to replace calcium in 
hydroxyapatite (Minkoff et al. 1987). 
Fluoride compounds (stannous fluoride in a 0.4% gel or sodium fluoride in a 0.5% mouthrinse or 
a 1.1% gel) have a valued action as an anti-cariogenic and desensitizing treatment (Featherstone. 
2000). Fluorides reduce the permeability of dentin by its ability to react with hydroxyapatite and 
form fluorapatite, which considered less susceptible to acid dissolution than hydroxyapatite 
(Morris et al 1999). 
Iontophoresis of fluoride has been used for the treatment of DH; however, its real benefit is 
debated. Iontophoresis has been described as a method of facilitating the transfer of ions by 
electrical potential into soft or hard tissues of the body for therapeutic purposes. Many studies 
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have found Iontophoresis a safe and effective method for treating cervical DH although some 
investigators consider it time-consuming and technique demanding. Many mechanisms have 
been proposed for its action. It may desensitize hypersensitive dentin by formation of a 
secondary dentin as a result of the electrical current applied or by increasing the concentration 
and depth of penetration of fluoride ions into dentinal tubules (precipitate calcium fluoride) 
thereby occluding the tubules and reducing the conduction of stimuli (Gillam et al. 1990) 
• Induction of natural mineral formation. 
As one of the difficulties with most of the desensitizing agents using the dentinal tubules’ 
occlusion technique is the inability to resist the chemical and mechanical challenges in the oral 
environment. Therefore, those necessitate the development of new technologies, which based on 
the stimulation of biological mineral development, such as the Pro-Argin technology, NovaMin 
bioactive glass and Casein Phosphopeptide-Amorphous Calcium Phosphate (CPP-ACP). It is 
believed to work through their binding to the exposed dentinal tubules to mediate the formation 
of biological minerals (Cummins 2010). 
Casein Phosphopeptide-Amorphous Calcium Phosphate (CPP-ACP), a milk derivative, was 
primarily developed for both anti-caries and enamel and dentin remineralization strategies rather 
than for the treatment of DH (Nongonierma and Fitzgerald. 2012). CPP is a bioactive peptide 
released from caseins with an enhanced binding ability to calcium. Amorphous calcium 
phosphate (ACP) has the ability to convert to hydroxyapatite in the presence of saliva. 
Accordingly, both calcium and phosphate were able to compose as a stable hydroxyapatite 
(Nongonierma and Fitzgerald. 2012).  
Bioactive glasses (calcium sodium phosphosilicate) which promote hydroxycarbonate apatite 
(HCA) participation. Investigations showed new calcium and phosphate development on dentin 
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surface and dentinal tubules’ occlusion afterward (Litkowski and Greenspan 2010, Pradeep and 
Sharma 2010). 
Pro-Argin, calcium carbonate and arginine complex as first formulated by Kleinberg (Kleinberg 
2002). This complex developed in order to simulate the natural process of DH reduction that 
happens in the presence of calcium, phosphate and glycoproteins in saliva. Naturally, Arginine is 
an amino acid found in saliva; it acts in combination with calcium carbonate and phosphate to 
create a plug in dentinal tubules that prevent fluid flow (Cummins 2010). The proposed 
mechanism of action states that the positively charged arginine is attracted to negatively charged 
dentine, and the alkaline pH promotes deposition of calcium, phosphate, arginine and carbonate 
at the dentine surface and inside the dentine tubules (Petrou et al. 2009). 
 
1.6.3.  Lasers: 
 
Laser therapy was first introduced as a potential method for treating dentinal hypersensitivity in 
1985  (Matsumoto et al. 1985). Generally, there are two types of lasers used for the treatment of 
dentin: low output power (low-level) lasers [helium-neon (He-Ne) and 
gallium/aluminum/arsenide (GaAlAs) (diode) lasers], and middle output power lasers (Nd: YAG 
and CO2 lasers). Lasers work by coagulation of proteins in the dentinal fluid and hence reduce 
permeability (Goodis et al. 1997). They are also believed to create an amorphous sealed layer at 
the dentine surface, which appears to be due to partial meltdown of the surface (Kumar et al 
2005). Nevertheless, lasers’ efficacy and mechanism of actions are questioned, due to deficient 
information related to the irradiation standards and guidelines (Sgolastra et al. 2011). 
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Even though, various methods available to treat or manage dentin hypersensitivity, none of them 
considered an ideal treatment that satisfies the gold standards.  
According to Holland, the ideal desensitizing agent should not irritate the pulp, should be 
relatively painless when applied or shortly afterward, should be easily applied, should act 
rapidly, should be permanently effective, should be cost-effective and should not discolor tooth 
structure (Holland et al. 1997). 
Based on a survey conducted regarding the diagnosis and treatment of DH within Northwest 
Practice-Based Research Collaborative in Evidence-Based Dentistry (PRECEDENT), a practice-
based dental research network. Information regarding types and frequency of use of different 
methods of diagnosis and treatment of DH was collected. The survey results imply that 
practitioners frequently use a wide variety of products and techniques to treat a patient with 
dentin hypersensitivity. Fluoride, glutaraldehyde / HEMA, bonding agents, potassium nitrates 
and restorative treatments were the common treatment and considered as a successful treatment, 
whereas observation, dietary and tooth brushing advice and lasers, as least successful (Cunha-
Cruz et al 2010).  
The variety of products and techniques used for the treatment of DH indicated a doubt among 
dentists about the best treatment option, as well as dissatisfaction with outcomes of available 
treatments. Which necessitate the conduction of a comparative effectiveness research and a 
practice analysis to provide dentists and patients with precise scientific information for 
comparing the effectiveness and safety of alternative treatment options in resolving DH among 
different available treatment.  
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2.  Evidence-Based Dentistry: 
Evidence-based dentistry (EBD) is systematic patient-centered researches that conducted by 
replicable methodologies and involve all implicate stakeholders.  
The ultimate goal of these researches is to translate all the information and knowledge about the 
best available health-care modalities for a certain patient in a specific clinical setting. According 
to the concept of EBD research, the best available health care means it is cost and safely 
effective aside with the best efficacy (Chiappelli. 2014). 
Basically, this coincides with the eventual aim of the translational effectiveness as part from the 
translational science. Translational science represented by two aspects; the translational research, 
which defined by The National Institutes of Health (NIH) as the transaction between the patient 
at the clinical setting and the fundamental pathobiology.  
The other aspect as described by the Agency for Healthcare Research Quality (AHRQ) is the 
utilization, application, and implications of the best available evidence in certain clinical settings. 
Eventually, Translational science results from a transaction between translational research and 
translational effectiveness (the translational research–effectiveness transaction, TRET) (Woolf. 
2008, Chiappelli. 2014) 
EBD relies on a systematic process of research synthesis that aims to develop a comparative 
efficacy and effectiveness research, review, and analysis, for practice (CEERAP), as well as to 
recognize the best available evidence to support any health care modalities (Chiappelli and 
Danaei. 2012) 
This systematic process starts from a research question (PICOTS) or a hypothesis, which defined 
the population of interest (P), the intervention (I), the comparator (C) and the clinical outcome 
(O) within a given timeline (T) and clinical setting (S).  
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Using the elements of the PICOTS research question to extract the related keywords and create 
the list of inclusion/exclusion criteria that facilitate the investigation of the entire relevant 
evidence (Bibliome). Then, a bibliome systematic screening is required to exclude irrelevant 
evidence that does not fit within the PICOTS question elements and the inclusion/exclusion 
criteria. Afterward, assessment of the quality and clinical relevance of evidence performed with 
validated reliable grading instruments intended to evaluate the strength of evidence, which are 
designed to quantify the quality of evidence based on recognized standards for research 
methodology, design, and statistical analysis (AHRQ, Methods Guide for Effectiveness and 
Comparative Effectiveness Reviews, 2014).  
The following step is data analysis, which comprises the acceptable sampling analysis. 
Essentially, translating the best available evidence is the ultimate goal of comparative efficacy 
and effectiveness research. Therefore, it is very important to conduct the acceptable sampling 
analysis to retain the high quality level of evidence (Chiappelli. 2014).   
Then, the systematic process of CEERAP concluded by developing an overarching statistical 
significance analysis between non-heterogeneous outcomes. Heterogeneity determined by the 
Cochran Q and I2 statistical tests.  Heterogeneity could be developed from original studies due to 
differences in participants, interventions, co-interventions, outcomes, measurements, settings and 
other factors varying within the data sets, studies, and participants. Meta-analysis conducted 
through two different methods based on the presence of certain extent of heterogeneity. 
Whereby, fixed or random model should be followed. Moreover, it is imperative to be aware of 
biases that may develop in the meta-analysis, which could be inherited from the primary 
evidence that represent variable biases within them or those that affect the overarching total body 
of evidence. 
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At the end, CEERAP produces the consensus of the best available evidence through the scientific 
process of research synthesis, which is reported in a scientific form as a systematic review 
(Chiappelli. 2014). 
 
3. Purpose of The Study: 
The aim of the study is to conduct a comparative effectiveness research to find out if In-office 
desensitizing agents with dentinal tubules occlusion mechanism of action are more effective than 
self-applied desensitizing toothpaste with the neural stimulus blocker mechanism of action in 
resolving dentin hypersensitivity.  
 
This drive the following PICOTS question:   
  
Population:  Adult patients (age 18<), diagnosed with dentine hypersensitivity due to exposed 
dentine. 
Intervention: In-office desensitizing agents with dentinal tubules occlusion mechanism of 
action. 
Comparator: Self-applied desensitizing toothpaste with the neural stimulus blocker mechanism 
of action 
Outcome: Pain and sensitivity reduction (Pain level) 
Timeline: 6 weeks or more. 
Setting: Any clinical practice  
 
 
18		
Chapter 2 
Methodology 
 
1. Hypothesis: 
• Research Hypothesis: In-office desensitizing agents with dentinal tubules occlusion 
mechanism of action are more effective than self-applied desensitizing toothpaste with a 
neural stimulus blocker mechanism of action in resolving dentin hypersensitivity. 
• Null Hypothesis: There is no difference in the desensitizing effect of In-office desensitizing 
agents with dentinal tubules occlusion mechanism of action compared to the self-applied 
desensitizing toothpaste with a neural stimulus blocker mechanism of action. 
 
2. Analytical Framework: 
The analytic framework represents relevant clinical concepts and refines the relationship 
between intermediate outcome measures and ultimate health outcomes. It helps in 
understanding the situation in which clinical decisions are made. (AHRQ, Methods Guide for 
Effectiveness and Comparative Effectiveness Reviews, 2014). 
Analytic framework was developed and associated with following key questions:  
1. Is the desensitizing agent effectiveness impacted by overall the oral environment? 
2. Is DH prevalence and treatment outcome impacted by gender? 
3. Is the desensitizing agent effectiveness enhanced by certain application technique?                
Figure (1) shows the analytic framework. 
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3. Search Strategy: 
The search for systematic reviews, randomized clinical trials and observational studies was done 
in March 2016 via electronic bibliographic databases using the following keywords: 
A. Dentin sensitivity, 
B. Dentin hypersensitivity, 
C. Tooth sensitivity, 
D. Dentin Desensitizing Agents,  
E. GLUMA  (Glutaraldehyde /2-hydroxyethyl methacrylate),  
F. Fluoride Compounds, 
G. Oxalate Product (Potassium), 
H. Calcium Phosphate,  
I. Arginine + Calcium Carbonate, 
J. Casein Phosphopeptide-Amorphous Calcium Phosphate  (CPP) – (ACP), 
K. Strontium Salts,  
L. Bioactive glass, 
M. Hydroxyapatites, 
N. Resin and adhesives,  
O. Dentin Bonding Agent,  
P. GIC / Glass Ionomer Cement, 
Q. Potassium Nitrate, 
R. Iontophoresis, 
S. Ozone. 
The Medical Subject Headings (MeSH) and Text Words used to preform the search strategy: 
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(((("Dentin Sensitivity"[Mesh]) OR ("dentin sensitivity"[text word] OR "dentin sensitivities"[text 
word] OR "dentin hypersensitivity"[text word] OR "dentin hypersensitivities"[text word] OR 
"dentine sensitivity"[text word] OR "dentine sensitivities"[text word] OR "dentine 
hypersensitivity"[text word] OR "dentine hypersensitivities"[text word]))) AND ("Dentin 
Desensitizing Agents"[Mesh] OR "Dentin Desensitizing Agents"[text word] OR 
"Fluorides"[Mesh] OR fluoride*[text word] OR "Denquel"[Supplementary Concept] OR 
"Isodan"[Supplementary Concept] OR "potassium nitrate"[Supplementary Concept] OR 
"Denquel"[text word] OR "Isodan"[text word] OR "potassium nitrate"[text word] OR "casein 
phosphopeptide-amorphous calcium phosphate nanocomplex" [Supplementary Concept] OR 
"CPP-ACP"[text word] OR "tooth mousse"[text word] OR "Recaldent"[text word] OR "casein 
phosphopeptide-amorphous calcium phosphate nanocomplex"[text word] OR "pro-argin" 
[Supplementary Concept] OR "pro-argin"[text word] OR proargin[text word] OR "Calcium 
Carbonate"[Mesh] OR "Oxalates"[Mesh] OR oxalate*[text word] OR oxalic[text word] OR 
Ethanedioic[text word] OR "Calcium"[Mesh] OR calcium[text word] OR "Calcium 
Phosphates"[Mesh] OR "Silicates"[Mesh] OR "calcium silicate" [Supplementary Concept] OR 
"BioAggregate" [Supplementary Concept] OR silicate*[text word] OR "gluma desensitizer" 
[Supplementary Concept] OR "Gluma" [Supplementary Concept] OR "Gluma Comfort Bond 
and Desensitizer" [Supplementary Concept] OR "Gluma One Bond" [Supplementary Concept] 
OR "Gluma 2000" [Supplementary Concept] OR gluma[text word] OR (("Glass"[Mesh] OR 
glass[text word]) AND bioactive[text word]) OR "Dentin-Bonding Agents"[Mesh] OR "Dentin-
Bonding Agents"[text word] OR "Dentin-Bonding Agent"[text word] OR "Glass Ionomer 
Cements"[Mesh] OR (("Glass Polyalkenoate"[text word] OR "Glass Ionomer"[text word]) AND 
cement*[text word]) OR "Resin Cements"[Mesh] OR "resin cement"[text word] OR "resin 
cements"[text word] OR "Iontophoresis"[Mesh] OR iontophores*[text word] OR 
"Strontium"[Mesh] OR "strontium chloride" [Supplementary Concept] OR "strontium-
containing hydroxyapatite" [Supplementary Concept] OR "strontium titanium fluoride" 
[Supplementary Concept] OR strontium[text word])) AND (("Clinical Trial "[Publication Type] 
OR "Randomized Controlled Trial "[Publication Type] OR "randomized"[tiab] OR 
"placebo"[tiab] OR "drug therapy"[sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab]) 
NOT ("animals"[MeSH] NOT "humans"[MeSH])) 
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3.1.  Search for Systematic Reviews: 
The search engines explored were: 
• The National Library of Medicine-PubMed, 
• Cochrane library,  
• American Dental Association (ADA) web Library. 
3.2.  Search for Randomized Clinical Trials: 
The search engines explored were: 
• The National Library of Medicine-PubMed, 
• Cochrane library,  
• American Dental Association (ADA) web Library. 
 
4. Determination of The Relevance: 
The relevance of the identified systematic reviews, clinical trials and observational studies to the 
study and PICOTS question was assessed using the following criteria: 
 
4.1.  Inclusion Criteria: 
• Assessment of DH using a scale for pain measurement for 6 weeks or more. 
• Treatment with in-office desensitizing agents with dentinal tubules occlusion mechanism of 
action. 
• Treatment with self-applied desensitizing toothpaste with neural stimulus blocker mechanism 
of action (5% Potassium Nitrate). 
• English language studies. 
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4.2.  Exclusion Criteria: 
• Post restorative treatment tooth sensitivity 
• Post-bleaching teeth sensitivity 
• Patients with active periodontal disease   
• Non English language papers 
 
4.3.  Adherence to The Proposed PICOTS Question: 
The PICOTS question was applied to the methodology and results of each study in order, to filter 
papers after applying the inclusion and exclusion criteria and to determine the faithfulness of 
each identified paper in the bibliome.  
 
5. Measurements: 
The quality of evidence and clinical relevance analysis achieved using validated and reliable 
instruments to allow a systematic evaluation of retained evidence. As recommended by the 
Cochrane group, the decision was done by two independent readers trained and standardized in 
the critical assessment of the principles of research methodology, design and statistical analysis 
and all disagreements resolved by discussion. Readers’ standardization and Inter-rater reliability 
of the two readers was evaluated by obtaining the Pearson correlation coefficient (r) and the 
shared variance (r2).  
° The correlation coefficient (r) between the two readers on three systematic reviews 
was 0.93 and the shared variance (r2) was 0.86 
° The correlation coefficient (r) between the two readers on three clinical trials was 
0.92 and the shared variance (r2) was 0.85 
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5.1.  Quality of Systematic Reviews:  
The revised Assessment of Multiple Systematic Reviews (R-AMSTAR) instrument utilized to 
assess and quantify the quality of retained systematic reviews (Kung et al. 2010). The R-
AMSTAR includes 11 questions, which cover 37 systematic review quality domains in a 
quantitative approach. Each question could score from 1 to 4 by which score 4 means all the 
criteria are fulfilled.  
• R-AMSTAR Items  
1. Was an ‘‘a priori’’ design provided? 
•  A clearly focused (PICO-based) question 
•  Description of inclusion criteria 
•  Study protocol is published and/or registered in advance 
2. Was there duplicate study selection and data extraction? 
• At least two persons independently extracted the data, explicitly stated 
• Statement of consensus procedure for disagreements 
• Disagreements among extractors resolved properly as stated or implied 
3. Was a comprehensive literature search performed? 
• At least two electronic sources are searched 
• Years and databases used are mentioned 
• Key words and/or MESH terms are stated and where feasible the search strategy outline 
is provided 
• Searches should are supplemented by consulting current contents, reviews, textbooks, 
registers and by reviewing the references in the studies found 
• Journals are hand-searched or manual searched 
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4. Was the status of publication (i.e., grey literature) used as an inclusion criterion? 
• The authors state that they searched for reports regardless of their publication type. 
• The authors state whether or not they excluded any reports based on their publication 
status, language etc. 
• “Non-English papers were translated “or readers sufficiently trained in foreign language 
• No language restriction or recognition of non-English articles 
5. Was a list of studies (included and excluded) provided? 
• List of included and excluded studies should be provided. 
• Table/list/figure of included studies, a reference list does not suffice 
• Table/list/figure of excluded studies either in the article or in a supplemental     source 
• Satisfactory/sufficient statement of the reason for exclusion of the seriously    considered 
studies 
• Reader is able to retrace the included and the excluded studies anywhere in the article 
bibliography, reference or supplemental source 
6. Were the characteristics of the included studies provided? 
• In an aggregated form such as a table, data from the original studies are provided on the 
participants, interventions/exposure and outcomes 
• Ranges are provided of the relevant characteristics in the studies analyzed 
• The information provided appears to be complete and accurate 
7. Was the scientific quality of the included studies assessed and documented? 
• ‘A priori’ methods are provided 
• The scientific quality of the included studies appears to be meaningful 
• Discussion/recognition/awareness of level of evidence is present 
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• Quality of evidence is rated/ranked base on characterized instruments 
8. Was the scientific quality of the included studies used appropriately in formulating 
conclusions? 
• The scientific quality is considered in the analysis and the conclusions of the review  
• The scientific quality is explicitly stated in formulating recommendations 
• Conclusions integrated/drives towards practice guidelines 
• Clinical consensus statement drives toward revision or confirmation of practice 
guidelines 
9. Were the methods used to combine the findings of studies appropriate? 
• Statement of criteria that were used to decide that the studies analyzed were similar 
enough to be pooled 
• For the pooled results, a test is done to ensure the studies were combinable, to assess their 
homogeneity 
• Recognition of heterogeneity or lack of thereof is present 
• If heterogeneity exists a ‘random effects model’ is used and/or the PEROSH OSH 
Evidence Methods AMSTAR items Criteria rationale of combining is taken into 
consideration 
• If homogeneity exists, author state a rationale or a statistical test 
10. Was the likelihood of publication bias assessed? 
• Recognition of publication bias or file drawer effect 
• Graphical aids (e.g. funnel plot) 
• Statistical tests (e.g. Egger regression test) 
11. Was the conflict of interest included? 
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• Statement of sources of support 
• No conflict of interest. This is subjective and may require some deduction or searching. 
• An awareness/statement of support or conflict of interest in the primary inclusion studies. 
 
5.2.  Quality of Clinical Trials:  
The quantified Risk of Bias instrument utilized to evaluate the quality of retained clinical trials 
(Barkhordarian et al. 2013). Originally, the qualitative Risk of Bias developed by the AHRQ to 
evaluate evidence systematically in four domains: (risk of bias, consistency, directness and 
precision) (Viswanathan et al. 2012) 
• Quantified Risk of Bias criteria  
i. Risk of Bias: Study design and study conduct for individual studies.  
Principle criteria (maximum score is 4) 
a. Bias in study design. 
b. Bias in methodology. 
c. Bias in study conduct 
 
ii. Consistency: Degree of similarity in the effect sizes of different studies within an 
evidence base 
Principle criteria (maximum score is 3) 
a. Inconsistent evidence bases have significant unexplained clinical statistical 
heterogeneity 
b. Meta-analysis should use appropriate test, Cochran’s Q test or 12 statistics. 
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iii. Directness: Either a single direct link between the interventions of interest and the 
ultimate health outcome under consideration or multiple links in a casual chain. With 
multiple links, strength of evidence is only as strong as the weakest link. 
Principle criteria (maximum score is 3) 
a. A single direct link between the interventions of interest and the ultimate health 
outcome under consideration. 
b. Reliance on multiple links, evidence of a casual chain (with multiple links, strength of 
evidence is only as strong as the weakest link). 
 
iv. Precision: The degree of certainty for estimate of effect with respect to a specific 
outcome. 
Principle criteria (maximum score is 4) 
a. Includes statistical significance for effect estimates. 
b. Includes confidence intervals for those effect estimates. 
c. Include any summary estimate of effect size. 
 
5.3.  Clinical Relevance Analysis: 
The Expansion in the Grading of Recommendations Assessment, Development and Evaluation 
(Ex-GRADE) was used to evaluate the clinical relevance and strength of recommendation. The 
strength of recommendation part includes 7 questions, each question could score from 1 to 4 by 
which score 4 means all the criteria are fulfilled (Phi et al. 2012) 
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• Ex-GRADE Items 
1 Are risk and affordability considered when given the recommendation for the intervention? 
 Principle criteria 
• Recognition of risk for the intervention is directly stated, or acknowledgement of risk can be 
inferred 
• Recognition of possible adverse effects post-intervention is directly stated, or 
acknowledgement of possible adverse effects post-intervention can be inferred 
• Recognition of cost for the intervention is directly stated, or approximate and/or relative cost 
for the intervention can be inferred 
• Recognition of affordability is directly stated or can be inferred. 
2. Are alternative recommendations given, if appropriate? 
Principle criteria 
• Alternative suggestions or recommendations were given with regards to risk during the 
intervention. 
• Alternative suggestions or recommendations were given with regards to possible adverse 
effects following the intervention. 
• Alternative suggestions or recommendations were given with regards to cost & affordability. 
• Explicitly states that no alternative recommendations are appropriate with regards to risk 
during the intervention. 
• Explicitly states that no alternative recommendations are appropriate with regards to possible 
adverse effects following the intervention. 
• Explicitly states that no alternative recommendations are appropriate with regards to cost & 
affordability. 
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3. Is availability of resources for the population of interest taken into account prior to 
formulating the recommendation? [Is the recommendation practical for the population of 
interest?] 
Principle criteria 
• Insurance coverage is available for the recommended intervention at hand [Some research on 
various insurance plans may need to be done] 
• Other alternative funding aside from insurance is available for the recommended intervention 
at hand [Some research for alternative funding may need to be done] 
• Resources in terms of equipment & supplies for the recommendation are easily accessible in 
clinical practice [This may require some prior knowledge of the equipment & supplies 
provided in the standard setting of the population of interest] 
4. Is a measureable guideline provided to monitor the intended outcome(s) of the 
recommendation? [Was there a method provided that can measure the effectiveness of the 
recommendations? How did they/will they measure the outcomes or results?] 
Principle criteria 
• Method of monitoring the intended outcome of the recommendation is given. 
• Method of monitoring the intended outcome can produce tangible data for the researcher. 
• Method of analyzing the data produced from monitoring the intended outcome is provided. 
5. Are the results of the intervention statistically significant? 
Principle criteria 
• Chosen methodology of the research is appropriate for the intended recommendation at hand. 
• Methodology of the research (e.g. methodology of the clinical trial, methodology of the 
systematic review, etc.) is executed properly & accurately. 
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• Statistical analysis of the data shows statistical significance with p < 0.05. 
6. Are the results clinically significant? 
Principle criteria 
For curative medicine/care, palliative medicine/care, or aesthetic/cosmetic care: 
• The intervention alters the pathophysiology of the disease/issue in question 
• The intervention can be realistically carried out & successfully executed in the clinical 
setting 
• The time it takes for noticeable results to be seen post-intervention is reasonable taking into 
consideration the total cost of the intervention (Cost = monetary expenses & risk, both during 
the intervention & post-intervention) 
7. Is the patient likely to comply with the suggested recommendation? 
Principle criteria 
• Minimal level of invasiveness to the patient 
• Minimal level of side effects after the given intervention 
• Benefits of the recommendation outweigh its total cost (Cost = monetary expenses & risk, 
both during the intervention & post-intervention) 
 
5.4.  Acceptable Sampling Analysis 
The Friedman test statistics for homogeneity of non-parametric analysis of factorial designs was 
done (Kung et al. 2010). Where, a significant result indicates heterogeneous scores, therefore a 
cut off of the low quality studies required to get more homogenous scores that represents a 
higher score among all evaluation domains as well as higher quality. MDAS (Medical Data 
Analysis System) program used for that. However, the bibliome was concerned with a body of 
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literature that has a considerable heterogeneity in term of quality of the evidence. Only two 
papers were left after the analysis, which precluded further work toward establishing the 
quantitative (i.e., by meta-analysis) and qualitative consensus of the best evidence. Therefore, an 
alternative approach for acceptable sampling was conducted. Whereby the top 20% highest 
scoring papers in the Bibliome were accepted by convention (Barkhordarian et al. 2013). 
 
5.5.  Overarching Statistical Significance: 
Meta-analysis was done on the two highest quality and homogenous clinical trials, based on the 
type of outcome mean and standard deviation obtained at baseline and different timeline 
evaluations. As meta-analysis could be conducted through the fixed or random model based on 
the presence of a certain extent of heterogeneity. Whereby, the fixed model assumes that the size 
of the treatment effect is fixed among all studies and all studies come from a common 
population. That is, if the sample size in each study were infinite, then the effect size in all 
studies would be identical and the variation gotten between studies resulted as a part of chance. 
While, the random model assumes that the treatment effect is varying between studies and 
samples are from populations with different effect sizes. Moreover, the actual effect in the 
studies might differ as the patient characteristics varied from one study to the next, or because 
the treatment itself varied as well as the outcome measure differed among the studies (Chiappelli 
2014).  
Based on the fact that these two studies are included randomly from a potentially large 
population of studies on the topic and as a part of distribution of such studies, thus the random 
method used, so that the result of the meta-analysis represents one of a several possible along 
that random distribution. 
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Chapter 3 
Results 
 
 
1. Search Results and Determination of the Relevance: 
 
1.1 Searches for Systematic Reviews: 
The initial systematic reviews search resulted in 54 studies. After duplicate and irrelevant studies 
exclusion, only 6 systematic reviews studies retained as relevant to the PICOTS question: 
1. Potassium containing toothpastes for dentine hypersensitivity. (Poulsen et al. 2006) 
2. The effect of calcium sodium phosphosilicate on dentin hypersensitivity: a systematic review 
and meta-analysis. (Zhu et al. 2015) 
3. Management of dentine hypersensitivity: efficacy of professionally and self-administered 
agents. (West et al. 2014) 
4. The efficacy of strontium and potassium toothpastes in treating dentine hypersensitivity: a 
systematic review. (Karim and Gillam 2013) 
5. In-office treatment for dentin hypersensitivity: a systematic review and network meta-
analysis. (Lin et al. 2012) 
6. Dentin hypersensitivity and oxalates: a systematic review. (Cunha-Cruz 2010) 
Figure (2) shows the summary of systematic review studies selection process. 
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1.2. Search for Randomized Clinical Trials: 
The initial search for randomized clinical trials, using PubMed, Cochrane central and ADA 
website search engines, resulted in 1272 studies. After duplicate removal, we got 611 studies. 
Then, 31 studies retained, as a relevant to the PICOTS question and after applying the 
inclusion/exclusion criteria:  
 
1. A clinical study of the effect of calcium sodium phosphosilicate on dentin 
hypersensitivity (Acharya et al. 2013). 
2. A clinical study comparing oral formulations containing 7.5 % calcium sodium 
phosphosilicate (NovaMin), 5% potassium nitrate and 0.4 % stannous fluoride for 
management of dentin hypersensitivity (Sharma et al 2010). 
3. Biomimetic mineralization: long-term observations in patients with dentin sensitivity 
(Guentsch et al. 2012). 
4. Treatments for hypersensitive non-carious cervical lesions: a practitioners engaged in 
applied research and learning (PEARL) network randomized clinical effectiveness study 
(Veitz-Keenan et al. 2013). 
5. Clinical evaluation of a resin-modified glass-ionomer liner for cervical dentin 
hypersensitivity treatment (Tantbirojn et al. 2006). 
6. Assessing the efficacy of three dentifrices in the treatment of dentinal hypersensitivity 
(Silverman et al. 1996). 
7. Treating cervical dentin hypersensitivity with fluoride varnish a randomized clinical 
study (Ritter et al. 2006). 
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8. Efficacy of a dentifrice containing potassium nitrate, soluble pyrophosphate, PVM/MA 
copolymer, and sodium fluoride on dentinal hypersensitivity: a twelve - week clinical 
study (Schiff et al. 1994). 
9. Randomized, placebo-controlled study of the efficacy of a calcium phosphate containing 
paste on dentin hypersensitivity (Mehta et al. 2015). 
10. Clinical effectiveness of two agents on the treatment of tooth cervical hypersensitivity 
(Kakaboura et al. 2005). 
11. Hydroxyapatite as an in-office agent for tooth hypersensitivity: a clinical and scanning 
electron microscopic study (Shetty et al. 2010). 
12. Evaluation of three different agents for in-office treatment of dentinal hypersensitivity: a 
controlled clinical study (Patil et al. 2015). 
13. Comparison of efficacy of three commercially available dentifrices on dentinal 
hypersensitivity: a randomized clinical trial (Pradeep et al. 2012). 
14. A randomized clinical trial of the desensitizing efficacy of three dentifrices (Schiff et al. 
2000). 
15. Efficacy of a dentifrice containing 5% potassium nitrate and 1500 PPM sodium 
monofluorophosphate in a precipitated calcium carbonate base on dentinal 
hypersensitivity (Schiff et al. 1998). 
16. Instant dentin hypersensitivity relief of a single topical application of an in-office 
desensitizing paste containing 8% arginine and calcium carbonate: A split-mouth, 
randomized-controlled study (Kapferer et al. 2012). 
17. A double blind controlled trial comparing three treatment modalities for dentin 
hypersensitivity (Brahmbhatt et al. 2012). 
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18. Comparison of two desensitizing agents for the treatment of cervical dentine sensitivity 
(Gillam et al. 1997). 
19. The long-term effectiveness of five current desensitizing products on cervical dentine 
sensitivity (Duran and Sengun. 2004). 
20. Effects of two topical desensitizing agents and placebo on dentin hypersensitivity (Vora 
et al. 2012). 
21. Comparison of two different forms of varnish in the treatment of dentine hypersensitivity: 
a subject- blind randomized clinical study (Sethna et al. 2011). 
22. Efficacy of two different CHX-containing desensitizers: a controlled double-blind study 
(Drebenstedt et al. 2012). 
23. Clinical evaluation of Prime & Bond 2.1 for treating cervical dentin hypersensitivity 
(Swift et al. 2001). 
24. Clinical efficacy of two dentin desensitizing agents (Morris et al. 1999). 
25. Efficacy of calcium sodium phosphosilicate in managing dentinal hypersensitivity (Surve 
et al. 2012). 
26. Randomized controlled clinical trial on the efficacy of dentin desensitizing agents (Mehta 
et al. 2014). 
27. Clinical evaluation of desensitizing treatments for cervical dentin hypersensitivity 
(Aranha et al. 2009). 
28. Clinical evaluation of a potassium nitrate dentifrice for the treatment of dentinal 
hypersensitivity (Nagata et al. 1994). 
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29. Comparison between effectiveness of a low-viscosity glass ionomer and a resin-based 
glutaraldehyde containing primer in treating dentine hypersensitivity—a 25.2-month 
evaluation (Polderman and Frencken 2007).  
30. Dentin desensitizing effects of Gluma Alternate, Health-Dent Desensitizer and Scotch 
bond Multi-Purpose (Dondi dall'Orologio et al. 1999). 
31. Desensitizing effects of Gluma and Gluma 2000 on hypersensitive dentin (Dondi 
dall’Orologio et al. 1993). 
Figure (3) shows the summary of Randomized Clinical Trial studies selection process. 
 
2.   Measurements and Quality Assessment: 
2.1.  Quality of Systematic Reviews:  
The revised Assessment of Multiple Systematic Reviews (R-AMSTAR) and the EX-GRADE 
instruments utilized to assess the quality and clinical relevance of six systematic reviews. Mean 
score from both readers were entered across the eleven domains of (R-AMSTAR) tool and the 
eight domains of (EX-GRADE) tool, each column corresponding to a certain question of the 
instruments. The marginal totals, means and standard deviations (horizontal marginal value) 
were used to assess the consistencies and to recognize the evidence strength across all domains 
for each paper. As a high mean of scores and low standard deviation signified higher quality 
evidence. While the vertical marginal totals, means and standard deviations would represents the 
relative strength of each domain across the bibliome where the high mean and low standard 
deviation indicated strength in that domain within the bibliome. Table (1) shows the scores of 
each systematic review, which fell within the confidence interval set by the sample (mean± 
standard deviation: 53.67 ± 9.61, CI95: 49.35 - 57.99) except for the (Zhu et al. 2015) study that 
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scored 67 as the highest score and the (Karim & Gillam 2013) study that scored 37 as the lowest 
score. R-AMSTAR domain represented by question 10 (publication bias assessment) have low 
mean value (1.83 ± 1.17) indicated a relatively weak domain among the bibliome. While, the 
EX-GRADE domains represented by question 2 (consideration of risk and affordability) with 
mean value (1.67 ± 0.82) and question 3 (recommendation of alternative) with mean value (1.83 
± 0.98) indicated relatively weak domains of clinical recommendations.    
 
2.2.  Quality of Clinical Trials:  
The quantified Risk of Bias and the EX-GRADE instruments utilized to evaluate the quality and 
clinical relevance of 31 clinical trials. Mean score from both readers were inserted across the 
four domains of (Risk of Bias) tool and the seven domains of (EX-GRADE) tool, each column 
corresponding to a certain question of the instruments. The marginal totals, means and standard 
deviations (horizontal marginal value) were investigated to evaluate the consistencies and to 
identify the evidence strength across all domains for each paper. The higher mean of scores and 
lower standard deviation implied higher quality evidence. While the vertical marginal totals, 
means and standard deviations would represents the relative strength of each domain across the 
bibliome where the higher mean and lower standard deviation indicated strength in that domain 
within the bibliome. Table (2) shows the scores of each clinical trial, which mainly fell within 
the confidence interval set by the sample (mean± standard deviation: 28.09 ± 3.05, CI95: 26.29 
to 29.9). However, It appears that seven studies scored above the confidence interval and six 
studies scored below the confidence interval. The consistency domain of the risk of bias 
instrument appears to have low mean value (1.98 ± 0.6) indicated a relatively weak domain 
among the bibliome. While, the EX-GRADE domains represented by question 2 (consideration 
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of risk and affordability) with mean value (1.58 ± 0.85) and question 3 (recommendation of 
alternative) with mean value (1.09 ± 0.30) indicated relatively weak domains of clinical 
recommendations.    
 
3.   Data Analysis: 
3.1.  Acceptable Sampling (Quality of the Systematic Review):  
A non-significant result of the Friedman test indicated homogeneous scores. Therefore, cut off of 
the low quality studies yielded only three out of six systematic reviews that considered as high 
quality studies:  
(Figure 4: Shows The Friedman test statistics for homogeneity for Systematic Review) 
1. Potassium containing toothpastes for dentine hypersensitivity. (Poulsen et al. 2006). 
2. The effect of calcium sodium phosphosilicate on dentin hypersensitivity: a systematic 
review and meta-analysis. (Zhu et al. 2015). 
3. Management of dentine hypersensitivity: efficacy of professionally and self-administered 
agents. (West et al. 2014). 
 
3.2.  Acceptable Sampling (Quality of the Clinical trials):  
A non-significant result of the Friedman test indicated homogeneous scores.  Thus, a cut off of 
the low quality studies yielded only two out of thirty-one clinical trials that considered as high 
quality studies:  
(Figure (5): Shows The Friedman test statistics for homogeneity for Clinical Trials). 
1. A clinical study of the effect of calcium sodium phosphosilicate on dentin 
hypersensitivity (Acharya et al. 2013). 
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2. A clinical study comparing oral formulations containing 7.5 % calcium sodium 
phosphosilicate (NovaMin), 5% potassium nitrate and 0.4 % stannous fluoride for 
management of dentin hypersensitivity (Sharma et al 2010). 
However, the bibliome was concerned with a body of literature that has a considerable 
heterogeneity in terms of quality of the evidence, which prevented further work toward 
establishing the quantitative and qualitative consensus of the best evidence. Therefore, an 
alternative approach for acceptable sampling was conducted. Whereby, a convention made to 
accept the top 20% highest scoring papers in the bibliome.  So, out of thirty-one studies, a total 
of seven studies were accepted: 
1. A clinical study of the effect of calcium sodium phosphosilicate on dentin 
hypersensitivity (Acharya et al. 2013). 
2. A clinical study comparing oral formulations containing 7.5 % calcium sodium 
phosphosilicate (NovaMin), 5% potassium nitrate and 0.4 % stannous fluoride for 
management of dentin hypersensitivity (Sharma et al 2010). 
3. Biomimetic mineralization: Long-term observations in patients with dentin sensitivity 
(Guentsch et al. 2012). 
4. Treatments for hypersensitive non-carious cervical lesions: a practitioners engaged in 
applied research and learning (PEARL) network randomized clinical effectiveness study 
(Veitz-Keenan et al. 2013). 
5. Clinical evaluation of a resin-modified glass-ionomer liner for cervical dentin 
hypersensitivity treatment (Tantbirojn et al. 2006). 
6. Assessing the efficacy of three dentifrices in the treatment of dentinal hypersensitivity 
(Silverman et al. 1996). 
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7. Treating cervical dentin hypersensitivity with fluoride varnish a randomized clinical 
study (Ritter et al. 2006). 
 
4. Data Extraction: 
Data extraction was done to obtain the study name (Author and publication year), study design, 
sample Size (Patient/Teeth)(Age/ Sex), intervention, comparator, assessment time points, method 
of assessment, method of pain assessment, DH baseline and oral hygiene and dietary counseling 
during the clinical trial.  
Table (3) shows the extracted data 
 
5. Overarching Statistical Significance: 
Based on the limited number of acceptable studies in terms of quality and the variation of 
interventions, including the mode of application and mechanism of action, the hydrodynamic 
stimuli applied, pain assessment methods used and the timeline evaluation all have contributed to 
the heterogeneity, which preclude their include in a single meta-analysis. Though, Meta-analysis 
was done on the two highest quality and homogenous clinical trials that tested the 5% potassium 
nitrate toothpaste compared to calcium sodium phosphsilicate toothpaste as at home 
interventions. Both studies reported the VAS scores to the air blast stimuli. The forest plot is 
presented in figure (6); a random model meta-analysis was used. “A” represents the 5% 
potassium nitrate group and  “ B ” represents the calcium sodium phosphsilicate group. There is 
a significant effect in favor of B across both studies and time points. The 4 weeks time point 
evaluation is significantly the best indicated by both studies as shown by the forest plot in figure 
(7). 
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Chapter 4 
Discussion  
 
The overall total scores of graded evidence reveal the extent of adherence to the commonly 
accepted criteria of quality of research synthesis. The analysis of the marginal mean and standard 
deviations (horizontal marginal values) reflects the relative strength or weakness of the bibliome 
among all domains. The result indicates that certain domains strong and acceptable in terms of 
quality and clinical relevance. Whereas, other domains are weak that might threaten the clinical 
recommendations determined by the investigated bibliome.  
     
1.  Consensus of The Best Available Evidence:  
 
1.1 Interpretations and Qualitative Consensus of Systematic Review: 
1.1.1. Potassium containing toothpastes for dentine hypersensitivity (Poulsen et al. 2006): 
This systematic review designed to evaluate the effectiveness of potassium-containing toothpaste 
in reducing DH. Studies that were included in the review were randomized control trials (RCTs) 
comparing potassium to non-potassium containing toothpaste that assessed at baseline and 6-8 
weeks after the treatment. Four methods were used to assess DH: tactile, thermal, air-blast, and 
patient’s subjective assessment of pain. The following databases were searched: Cochrane Oral 
Health Group Trials Register (searched until August 2005); CENTRAL (until August 2005); 
EMBASE/MEDLINE, PubMed, Web of Science (until September 2005). Six studies only 
satisfied the inclusion criteria for this review, which showed the statistically significant effect of 
potassium nitrate toothpaste on air blast and tactile sensitivity at the 6 to 8 weeks follow up. 
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However, the subjective assessment failed to show a significant effect at the 6 to 8 week 
assessment. 
 
1.1.2. The effect of calcium sodium phosphosilicate on dentin hypersensitivity: a systematic 
review and meta-analysis (Zhu et al. 2015): 
Generally, This systematic review conducted to assess the effect of using Calcium Sodium 
Phosphosilicate (CSPS) to treat DH compared with that of a negative (placebo) control. Five 
databases used for search of randomized controlled trials (RCTs) until January14, 2015: Medline 
(via PubMed), EMBASE, Web of Science, CENTRAL (The Cochrane Library) and the Chinese 
Biomedical Literature Database. DH pain was assessed by tactile, evaporative, or thermal 
stimuli, and reported self-assessed sensitivity. Different scales were used to quantify DH; 10-cm 
visual analog scale (VAS) was the most commonly used for measurements. Two of the studies 
included showed an advantage of a professionally applied prophylaxis paste containing 15% 
CSPS compared with a negative control in the management of DH immediately after prophylaxis 
and at 4 weeks, as determined using evaporative or tactile stimuli. The observation of adverse 
reactions absence during the study period mentioned in these studies, although other studies 
reported minor adverse response such as; soft tissue irritation gastrointestinal disorders, 
infections, injury, poisoning and procedural complications, and nervous system disorders. 
Additionally, the included studies were industry-sponsored, which may impact the outcome of 
studies. 
 
1.1.3.  Management of dentine hypersensitivity: efficacy of professionally and self-administered 
agents (West et al. 2015): 
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This systematic review included various treatment modalities for dentine hypersensitivity. 
Randomized controlled trials retained were diverse in design, study period, negative and positive 
controls and comparator products investigated. DH assessed with multiple stimuli: air-blast and 
tactile or thermal stimuli. Three databases (PubMed, Medline and Cochrane clinical trials 
database) and hand searches were used from 14–21 July 2014 to identify randomized controlled 
trials. Assessing and driving decisive statements about the treatment effectiveness were difficult 
due to various reasons. For instance, different active ingredients were evaluated, the presence of 
additional ingredients that might have an impact on the management of dentine hypersensitivity. 
This review revealed limited evidence about the effectiveness of potassium salts for dentine 
hypersensitivity management. As the low quality of evidence doesn’t support potassium being as 
effective as other positive control agents, or more effective than negative controls. In regard to 
the In-office desensitizing agents, the outcomes of the review suggest that professionally applied 
arginine, Calcium sodium phosphosilicate (CSPS), oxalates and resins are effective for the 
treatment of dentine hypersensitivity; although, available evidence weren't adequate to support 
these agents compared to other professionally applied agents. Generally, In-office desensitizing 
agents seem to be an effective approach for the treatment of dentine hypersensitivity; however, 
there is unsatisfactory evidence to recommend one agent compared to another. 
 
 1.2 Interpretations and Qualitative Consensus of Clinical Trials: 
 1.2.1.  A clinical study of the effect of calcium sodium phosphosilicate on dentin 
hypersensitivity (Acharya, 2013): 
This clinical trial conducted to assess the efficacy and safety of a desensitizing agent containing 
calcium sodium phosphosilicate toothpaste compared to 5% potassium nitrate containing 
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toothpaste. Air evaporative stimulus and visual analog scale (VAS) used to assess and measure 
sensitivity level. Hypersensitivity reduction observed in all treatment groups from baseline to 2, 
4 and 8 weeks that increased with time of treatment. The potassium nitrate group showed a 
reduction in sensitivity but reduction compared with the calcium sodium phosphosilicate group 
was less at 2 weeks. However, it was found to be as effective as calcium sodium phosphosilicate 
at 8 weeks. Since calcium sodium phosphosilicate showed a greater reduction in sensitivity 
compared to potassium nitrate at an earlier stage, which could be explained by the fact that 
calcium sodium phosphosilicate act faster than potassium nitrate. Clinically, it is very important 
to have faster relief of dentinal hypersensitivity. 
 
1.2.2   A clinical study comparing oral formulations containing 7.5 % calcium sodium 
phosphosilicate (NovaMin), 5% potassium nitrate and 0.4 % stannous fluoride for management 
of dentin hypersensitivity (Sharma el al 2010): 
The clinical trial aimed to compare the clinical effectiveness of 7.5% calcium phosphosilicate 
(NovaMin), 5% potassium nitrate and 0.4% stannous fluoride for DH management. Sensitivity to 
cold water and air blast stimuli measured with visual analog scale (VAS) at baseline, two, four, 
and 12 weeks. The study concluded that potassium and stannous fluoride desensitizing agent 
show similar efficacy. However, compared to calcium phosphosilicate, the sensitivity reduction 
significantly inferior in the first two weeks and almost the same at 12-week assessment. Which 
explained by the fact that calcium phosphosilicate has rapid effectiveness and not sustainable 
compared to 5% potassium nitrate. 
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1.2.3.   Biomimetic mineralization: long-term observations in patients with dentin sensitivity 
(Guentsch 2012): 
This clinical trial conducted to assess the effectiveness of a biomimetic mineralization system 
(BIMIN) compared to Gluma Desensitizer as in-office DH treatment approach. Air blast stimuli 
and Visual-Analog-Scale (VAS) used to assess the sensitivity level at baseline (pre-treatment), 2 
days, 4, 8 and 12 weeks, and 12 months post-treatment. The study concluded that both treatments 
approach resulted in statistically significant reductions in sensitivity and VAS scores through all 
time assessment and differences between the two approaches were statistically not significant. 
  
1.2.4.   Treatments for hypersensitive non-carious cervical lesions: a practitioners engaged in 
applied research and learning (PEARL) network randomized clinical effectiveness study (Veitz-
Keenan et al. 2013): 
This clinical study designed to determine the effectiveness of three approaches for DH 
management: 5% potassium nitrate toothpaste as at-home approach for hypersensitivity 
treatment, the application of a resin-based composite restoration and sealant. Air blast 
stimulation and Numeric Pain Assessment Scale (NPAS) used to evaluate the sensitivity level at 
baseline and at one, three and six months. The study outcome showed that throughout the 
evolution period, both the sealant and the resin-based composite restoration treatment approaches 
demonstrated a comparable effectiveness in reducing hypersensitivity. Although, the 
complicated procedure of application of the restoration compared with the sealant might be 
considered in terms of time and cost in treating dentin hypersensitivity. 5% potassium nitrate 
toothpaste was not as effective, nevertheless, the reduction in the hypersensitivity increase with 
each recall that suggests the slow effectiveness of 5% potassium nitrate. 
46		
1.2.5.  Clinical evaluation of a resin-modified glass-ionomer liner for cervical dentin 
hypersensitivity treatment (Tantbirojn et al. 2006): 
The aim of this clinical trial is to evaluate the effectiveness of resin-based Gluma desensitizer 
and glass ionomer liner material in treating dentin hypersensitivity. Tactile stimulus and cold test 
used then pain level measured with visual analog scale (VAS). Sensitivity assessment was done 
at baseline, after treatment at 1 week, 1, 3, 6, and 12 months. The study results showed a 
sensitivity reduction for both treatment options up to one year; however, with glass ionomer liner 
was significantly superior in sensitivity reduction than Gluma. With glass ionomer liner 
treatment option there is a tendency to perform an overhang at the gingival margins, which 
contribute to the development of gingivitis. Also, the development of local burning sensation in 
the buccal mucosa with Gluma application reported in this clinical trial. 
 
1.2.6.  Assessing the efficacy of three dentifrices in the treatment of dentinal hypersensitivity 
(Silverman et al. 1996): 
This clinical trial aimed to evaluate the desensitizing effectiveness and safety of the 5% 
potassium nitrate and 0.243 % sodium fluoride formulation, 5% potassium nitrate formulation 
and 10 % strontium chloride compared to placebo as control and to each other. Cold-air and 
tactile stimuli followed by visual analog scale (VAS) sensitivity assessment used throughout 
baseline, two-week, four-week and eight-week study period. Additionally, an oral soft tissue 
examination conducted to assess the safety of the agents. Generally, the study results showed 
that, at eight-weeks assessment, both 5 % potassium nitrate toothpastes were significantly greater 
than 10% strontium chloride in DH management. In terms of safety, 5 % potassium nitrate based 
toothpaste provides a safe treatment approach. 
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1.2.7.  Treating cervical dentin hypersensitivity with fluoride varnish - a randomized clinical 
study (Ritter et al. 2006): 
This clinical trial purpose was to evaluate the immediate and 24-week efficacy of two fluoride 
varnishes with similar active ingredients in reducing dentin hypersensitivity. Compressed air and 
cold stimuli used then followed by visual analog scale (VAS) assessment. Dentinal 
hypersensitivity evaluated at five-time points: enrollment (six-weeks before treatment), end of 
the run-in period (baseline), two weeks after treatment, eight weeks after treatment and 24 weeks 
after treatment. The study concluded that DH reduced after single application of both types to 
fluoride varnishes at 24 weeks assessment with no significant differences between the 
desensitizing efficacy of this varnish and that of the control varnish. Moreover, the study 
provided evidence regarding the safety of these agents with the absence of any subjective or 
objective soft-tissue irritation. 
 
2. Quantitative Consensus of Systematic Review: 
The limited number of studies included in the meta-analysis prevented the founding of high 
power meta-analysis. Yet, we can infer that 5% potassium nitrate toothpaste has inferior 
effectiveness in DH management as at home intervention. 5% potassium nitrate toothpaste 
compared to calcium sodium phosphsilicate toothpaste as at home intervention had a very slow 
effectiveness. Calcium sodium phosphsilicate toothpaste at 4 weeks time point evaluation is 
significantly the best indicated by both studies, however, that effectiveness is not sustained 
beyond 4 weeks to be comparable to 5% potassium nitrate effectiveness after that. 
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Chapter 5 
Conclusion  
 
In conclusion, based on the qualitative analysis of this review, the 5% potassium nitrate 
toothpaste has inferior effectiveness in DH management as at home intervention, however, the 
reduction in the hypersensitivity increase with each recall that suggests the slow effectiveness 
that could be explained by the requisite of maintaining a high level of potassium nitrate to reach 
the maximum effectiveness.  5% potassium was not effective compared to in-office desensitizing 
intervention. Although it is difficult to prove or reach a conclusive evidence of the best treatment 
option, treatment approaches with resin-based composite restoration and glass ionomer liner 
resulted in statistically significant reduction in sensitivity. Yet, the complicated procedure of 
application of these restorations might be considered in terms of time and cost in treating dentin 
hypersensitivity. Furthermore, it considered as technique sensitive owing to the tendency to 
perform an overhang at the gingival margins, which contribute to the development of gingivitis 
or jeopardize the biological width of the periodontal tissues. Gluma and fluoride varnishes were 
effective in reducing DH for up to 6 months with no reported adverse effects aside to the time 
and cost consideration. 
This review shed the light on current deficiencies and weakness in the clinical trials that 
conducted to evaluate DH intervention.  Essentially, these necessitate the creation of efficient 
and comprehensive standards and guidelines for these clinical trials in order to overcome 
existing weakness in the field. Furthermore, considering the field weakness in the future studies 
will help to achieve a decisive evidence to support the best DH treatment options and increase 
the extent of reliability.  
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1. Limitation:  
 
1.1. Study Limitation: 
 
First of all, selection bias may have arisen, as a result of language restriction to only English 
publications.  Also, the variation of interventions, including the mode of application and 
mechanism of action, the hydrodynamic stimuli applied, pain assessment methods used and the 
timeline evaluation all add to the deficiencies in the design and methodology of the clinical trials, 
which have contributed to the heterogeneity as well as in a low power for meta-analyses. 
Additionally, the stringent method for acceptable sampling using the Friedman test for non-
parametric analysis of factorial designs contribute to the limited number of acceptable studies in 
terms of quality across all evaluation domains, which also prevented the founding of high power 
meta-analysis. 
Furthermore, the quality of evidence could vary based on the instruments used for its 
measurement and grading. The degree of domains convergence across the measurement 
instruments might differ and the amount of agreement between measurement approaches for 
quality rating diverge. There is less or more emphasis on different criteria and inconsistency in 
terms of domains used to assess the evidence quality. Therefore, the use of limited measurement 
instruments could contribute to the presence of bias in assessing quality. 
 
1.2. Field Limitation: 
Regardless the numerous DH intervention options that are available and the conducted clinical 
trials to demonstrate their efficacy, it is still difficult to prove or reach a conclusive evidence of 
the best treatment option. This could be as a result of the subjective nature and complexity of 
pain. As patients’ response to different stimuli might be influenced by different factors such as 
individualized pain perception, psychological and emotional factors. Furthermore, the influence 
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of placebo effect and Hawthorne effect might be involved in the complexity of DH pain 
measurement. Although double-blind placebo-controlled studies could help in overcoming the 
influence of placebo effect and Hawthorne effect, it remains a challenge in the actual clinical 
setting. Moreover, the clinical trials designed to evaluate DH treatment options highly 
contributed to the inconclusive outcome. As the diversity of stimuli methods used to provoke 
pain to be measured, acquire a lot of deficiencies that impacts their reproducibility and 
complicate pain monitoring among the trials. Additionally, lacking standardized oral hygiene 
instructions, including toothpaste used and brushing technique during the trials aside to the 
indefinite dietary regimen. All could contribute to the oral environment alteration that involved 
with the demineralization - remineralization cycle and biased the outcome.    
Pulp and dentin tissue are vital tissues that normally react to physiological stimuli. As in some 
patients with dentin hypersensitivity, a self-defense mechanism by secondary dentin lay down 
might occur with time, in order to reduce the fluid flow within the dentinal tubules as well as 
sensitivity feeling. Consequently, that might contribute to the false-positive outcome during the 
clinical trials. Therefore, clinical trials designed to assess DH treatment must be conducted 
within a time frame that not exceed the dentin-pulp physiological response, which need to be 
determined.  
Furthermore, the concern of industry-sponsored clinical trial in this field will preclude any 
decisive clinical recommendation regarding the treatment option and increase the risk of 
publication bias.  
The comprehensive assessment of the clinical findings should not be one-sided and based only 
on the subjective-based interpretation of the patient’s pain response. However, additional 
objective assessment methods are needed such as the hormone level assay. Several salivary 
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biomarkers have been identified to be associated with pain and stress including salivary amylase, 
cortisol, substance P, lysozyme and secretory IgA (Malamud and Rodriguez-Chavez. 2011). 
Furthermore, the correlation between pain responses in dental pulp and neuropeptides, including 
calcitonin gene-related peptide (CGRP), substance P, neurokinin A and neurokinin P have been 
investigated (Malamud and Rodriguez-Chavez. 2011). A significant correlation between visual 
analog scale (VAS) and salivary alpha amylase was found, which suggest that this biomarker 
may be a suitable indicator for the objective assessment of pain intensity (Shirasaki et al. 2007). 
Utilizing salivary biomarker to assess hormones associated with pain has the advantage of 
avoiding pain and stress might cause by other invasive methods. 
 
2. Clinical Recommendations: 
It is essential to diagnose DH and identify the predisposing factors in order to effectively manage 
DH and improve patients’ quality of life by developing a management approaches that integrate 
preventative and treatment aspects. Beginning with the proper oral hygiene practices including 
timing of tooth brushing as brushing following an acid challenge may lead to further loss of hard 
tissue. Additionally, it is important to provide an appropriate dietary advice based on the analysis 
of dietary habits. This will help providing a personalized DH treatment and prevention. As this 
review concluded that 5% potassium nitrate toothpaste has inferior effectiveness in DH 
management as at home intervention, while the reduction in the hypersensitivity increase with 
each recall that suggests the slow effectiveness that could be explained by the requisite of 
maintaining a high level of potassium nitrate to reach the maximum effectiveness, which might 
be impossible in the oral environment.  
Though it is challenging to verify or reach a conclusive evidence of the best treatment option, 
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treatment approaches with resin-based composite restoration and glass ionomer liner resulted in 
statistically significant reduction in sensitivity. Nevertheless, time and cost consideration arise 
due to the complicated procedure of application of these restorations. In addition, Gluma and 
fluoride varnishes were effective in reducing DH for up to 6 months with no reported adverse 
effects beside to the time and cost consideration.  
The challenges to achieve a decisive evidence to support the best DH treatment options highlight 
the extent of heterogeneity and quality inferiority of clinical trials in the field, which impact the 
degree of their reliability. These require the future conduction of well-constructed clinical trials 
that directed to overcome current deficiencies and weaknesses in the field.  
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Tables 
 
 
  
Table (1): Systematic Reviews Grading Scores (R-AMSTAR and EX-GRADE Instruments)  
 
 
 EX-GRADE R-AMSTAR 
Systematic 
Review 
Q 
1 
 Q 
 2 
Q 
3 
Q 
4 
Q 
5 
Q 
6 
Q 
7 
Q 
8 
Q 
9 
Q 
10 
Q 
11 
Q 
1 
Q 
2 
Q 
3 
Q 
4 
Q 
5 
Q 
6 
Q 
7 
Q 
8 
T
otal 
M
ean 
SD
 
Zhu et 
al. 2015 4 4 3 
 
3 
 
4 4 4 4 4 4 4 4 3 3 2 3 4 3 3 67 3.56 0.61 
Poulsen 
et al. 
2006 
4 3 4 4 4 3 4 4 3 2 1 3 1 1 2 4 2 3 3 55 2.89 1.10 
West et 
al. 2014 3 4 4 2 3 4 4 4 1 2 4 3 1 1 2 4 3 3 3 55 2.89 1.10 
Cunha-
Cruz 
2010 
4 4 4 4 4 4 3 3 2 1 1 2 2 3 2 4 2 3 3 55 2.89 1.04 
Lin et 
al. 2013 3 4 4 2 4 4 3 2 3 1 3 2 2 2 2 3 3 3 3 53 2.79 0.85 
Karim 
& 
Gillam 
2013 
3 4 3 2 4 4 1 1 1 1 1 1 1 1 2 2 1 1 3 37 1.95 1.18 
Mean 3.5 3.83 3.67 2.83 3.83 3.83 3.16 3 2.33 1.83 2.33 2.5 1.67 1.83 2 3.33 2.5 2.67 3 53.66   
SD 0.55 0.41 0.52 0.99 0.41 0.41 1.17 1.26 1.21 1.17 1.51 1.05 0.82 0.98 0 0.82 1.05 0.82 0 9.61   
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Table (2): Clinical Trials Grading Scores (Risk of Bias and EX-GRADE Instruments)  
 
  
 
Clinical 
Trials 
Risk of Bias EX-GRADE T
otal 
M
ean 
SD
 Risk of 
Bias Consistency Directness Precision 
Q 
2 
Q 
3 
Q 
4 
Q 
5 
Q 
6 
Q 
7 
Q 
8 
Acharya et 
al. 2013 3 3 3 3 3 1 2 4 4 4 4 34 3.09 0.94 
Sharma et 
al 2010 4 3 2 3 3 1 2 4 4 4 4 34 3.09 1.04 
Guentsch et 
al. 2012 4 2 3 3 1 1 2 4 4 4 4 32 2.90 1.22 
Veitz-
Keenan et 
al. 2013 
4 3 3 3 2 1 2 4 3.5 3 3 31.5 2.86 0.89 
Tantbirojn 
et al. 2006 3 2 3 3 3 1 2 4 4 3 3 31 2.82 0.87 
Siverman et 
al. 1996 3 2 2 3 3 1 2 4 3 4 3 30 2.73 0.90 
Ritter et al. 
2006 3 3 3 3 1 1 2 4 4 3 3 30 2.73 1.01 
Schiff et al. 
1994 2.5 2 2 2 3 1 2 4 3 4 4 29.5 2.68 1.01 
Mehta et al. 
2015 3 2 2 2 3 1 1 4 4 4 3 29 2.64 1.12 
Kakaboura 
et al. 2005 3 2.5 2.5 3 1 1 2 4 4 3 3 29 2.64 1.00 
Shetty et al. 
2010 3 2 2 3 1 1 2 4 4 3 4 29 2.64 1.12 
Patil et al. 
2015 3 2 3 3 1 1 2 4 4 3 3 29 2.64 1.03 
Pradeep et 
al. 2012 3 3 2 2 2 1 2 4 4 3 3 29 2.64 0.92 
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Table (2): Clinical Trials Grading Scores (Risk of Bias and EX-GRADE Instruments) (Continue) 
 
 
Clinical 
Trials 
Risk of Bias EX-GRADE Total 
M
ean 
SD 
Risk 
of 
Bias 
Consistency Directness Precision Q 2 
Q 
3 
Q 
4 
Q 
5 
Q 
6 
Q 
7 
Q 
8 
Schiff et al. 
2000 3 2 2 2 2 1 2 4 3.5 3 4 28.5 2.59 0.97 
Schiff et al. 
1998 2 2 2.5 2 1 2 2 4 3 4 4 28.5 2.59 1.02 
Kapferer et 
al. 2013 2 2 3 3 1 1 2 4 4 3 3 28 2.54 1.04 
Brahmbhatt 
et al. 2012 3 1 3 2 1 1 2 4 4 3 4 28 2.54 1.21 
Gillam et 
al. 1997 2 2 2 3 1 1 2 4 4 3 4 28 2.54 1.13 
Duran & 
Sengun. 
2004 
3 2 2 3 1 1 2 4 4 3 3 28 2.55 1.03 
Vora et al. 
2012  3 2 2 3 1 1 2 4 4 3 3 28 2.55 1.04 
Sethna et 
al. 2011 3 2 2 2 1 2 2 4 3 4 3 28 2.55 0.93 
Drebenstedt 
et al. 2012 3 2 2 3 1 1 2 4 3 3 3 27 2.45 0.93 
Swift et al. 
2001 2 1 3 3 1 1 2 4 4 3 3 27 2.45 1.13 
Morris et 
al. 1999 2 2 2 4 1 1 2 4 3 3 3 27 2.45 1.04 
Surve et al. 
2012 2 1 2 2 3 1 2 3 3 4 4 27 2.45 1.04 
Mehta et al. 
2014 3 2 2 3 1 1 1 3 4 3 3 26 2.36 1.03 
Aranha et 
al. 2009 2 2 2 3 1 1 2 4 3 3 3 26 2.36 0.92 
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Table (2): Clinical Trials Grading Scores (Risk of Bias and EX-GRADE Instruments) (Continue) 
 
 
Clinical 
Trials 
Risk of Bias EX-GRADE  Total 
 M
ean 
SD 
Risk 
of 
Bias 
Consistency Directness 
Precisio
n 
Q 
2 
Q 
3 
Q 
4 
Q 
5 
Q 
6 
Q 
7 
Q 
8 
Nagata et 
al. 1994 2 2 3 2 1 1 2 3 3 2.5 3 24.5 2.23 0.75 
Polderman 
& 
Frencken 
2007 
2 1 3 2 1 1 2 2 3 3 3 23 2.09 0.83 
Dondi 
dall'Orolo
gio et al. 
1999 
1 1 2 2 2 2 2 2 1 3 3 21 1.91 0.70 
Dondi 
dall'Orolo
gio et al. 
1993 
2 1 2 3 1 1 2 2 2 2 2.5 20.5 1.86 0.63 
Mean 2.69 1.98 2.39 2.68 1.58 1.09 1.94 3.71 3.48 3.24 3.31 28.09   
SD 0.69 0.61 0.48 0.54 0.85 0.30 0.25 0.64 0.71 0.53 0.49 3.05   
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Table (3): Extracted Data 
 
Study RCT 
(Authors /year) 
Extracted Data 
Acharya et al. 
2013 
Study design: Randomized, double blind and parallel group clinical trial 
Sample Size: 20 Patient (18 - 65 years) 
Intervention: 5% Calcium Sodium Phosphosilicate 
Comparator: 5% Potassium Nitrate (positive control) 
Assessment Time points: Baseline, 2, 4 and 8 weeks 
Method of Assessment: Cold pack test / controlled air pressure  
Method of Pain assessment: 10 cm (VAS) 
DH Baseline: VAS  > 5 cm 
Oral Hygiene: Yes 
Dietary counseling: Yes 
 
Sharma et al. 
2010 
 
Study design: Single center randomized double blind parallel group design 
Sample Size: 120 Patient (20-50 years) 
Intervention: 7.5 % Calcium Sodium Phosphosilicate (NovaMin) 
Comparator: 5% Potassium Nitrate 
                      0.4 % Stannous Fluoride 
Assessment Time points: 2, 4 and 12 weeks 
Method of Assessment: Air Blast/ cold water 
Method of Pain assessment: 10 cm (VAS)  
DH Baseline: VAS  >5 cm 
Oral Hygiene: Yes 
Dietary counseling: No 
Arndt et al. 2012 Study design: Single-blind, 2-arm trial 
Sample Size: 40 Patients (111 teeth) 
Intervention: Biomimetic mineralization system (BIMIN) 
Comparator: Gluma desensitizer 
Assessment Time points: 2 days, 4, 8, 12 weeks and 12 months 
Method of Assessment: Air stimulation / Impression 
Method of Pain assessment: 100 mm (VAS) / SEM analysis 
DH Baseline: VAS   >50 mm 
Oral Hygiene: No 
Dietary counseling: No 
Veitz-Keenan et 
al. 2013 
 
Study design: Three-armed randomized clinical effectiveness study 
Sample Size: 304 patient 
Intervention: Sealant  (The DBA and resin layer)/Flowable composite resin 
Comparator: 5% Potassium Nitrate and 0.2 % Sodium Fluoride 
Assessment Time points: Baseline, 1, 2 and 6 months 
Method of Assessment: Air-blast  
Method of Pain assessment: (0–10) Numeric Pain Assessment Scale  
                                             Questionnaires 
DH Baseline: NPAS > 3 
Oral Hygiene: Yes 
Dietary counseling: No 
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Table (3): Extracted Data (Continue) 	
 Study RCT 
(Authors /year) 
Extracted Data 
Tantbirojn et al. 
2006 
Study design: Split-mouth randomized controlled clinical trial 
Sample Size: 44 Patients / 106 teeth (22-68 years) 
Intervention: (Liquid/ Paste) Resin-Modified Glass-Ionomer liner 
Comparator: Gluma 
Assessment Time points: Baseline, After Tx, 1 week, 1,3,6 and 12 months 
Method of Assessment: Tactile stimulus / cold test 
Method of Pain assessment: 10 cm (VAS) 
DH Baseline: At least 2 cm 
Oral Hygiene: No 
Dietary counseling: No 
Silverman el al, 
1996 
Study design: Double-blind, parallel design clinical trial 
Sample Size: 230 patient (mean 41 years) 
Intervention: 5 % potassium nitrate: 0. 243% sodium fluoride dentifrice 
                      5 % potassium nitrate' 
                     10 % strontium chloride 
Comparator: Placebo 
Assessment Time points: 4 and 8 weeks 
Method of Assessment: Cold-air sensitivity /Tactile sensitivity  
                                      Questionnaire examination 
Method of Pain assessment: 100 mm (VAS) / Yeaple probe 
DH Baseline:  (VAS) 30 – 70 mm 
                       Probe 10 to 50 grams 
Oral Hygiene: Yes 
Dietary counseling: No 
Ritter el al. 2006 Study design: Subject-blind randomized clinical trial 
Sample Size: 19 patient / 59 teeth 
Intervention: Fluoride varnish 
Comparator: Fluoride varnish 
                      No placebo 
Assessment Time points: (Baseline), 2, 8 and 24 weeks 
Method of Assessment: Compressed air / Cold stimulus 
Method of Pain assessment: 100 mm (VAS) 
DH Baseline: Moderate / sever. 
Oral Hygiene: Yes 
Dietary counseling: No 
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Figures 
 
 
 
Figure (1): Analytic Framework
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Figure (2): Summary of Systematic Review Studies Selection Process 
 
 
 
 
 
Figure (3): Summary of Randomized Clinical Trials Studies Selection Process 
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Sample Rank Sum Mean Ranks Median 
1 14 7 3.5 
2 10 5 3 
3 7.5 3.75 2.5 
4 10 5 3 
5 10 5 3 
6 2 1 1 
7 4.5 2.25 2 
8 18.5 9.25 4 
9 18.5 9.25 4 
10 18.5 9.25 4 
11 18.5 9.25 4 
Cases: 2 
Chi-Square: 16.4318 
df: 10 
Prob: .0879 
Epsilon Squared: .2014 
Sample Rank Sum Mean Ranks Median 
1 39.5 13.1667 4 
2 39.5 13.1667 4 
3 37 12.3333 4 
4 26 8.6667 3 
5 39.5 13.1667 4 
6 39.5 13.1667 4 
7 46 15.3333 4 
8 46 15.3333 4 
9 25.5 8.5 3 
10 24 8 2 
11 32 10.6667 4 
12 33 11 3 
13 9 3 1 
14 9 3 1 
15 11 3.6667 2 
16 37 12.3333 4 
17 28.5 9.5 3 
18 24 8 3 
19 24 8 3 
Cases: 3 
Chi-Square: 24.9842 
df: 18 
Prob: .1254 
Epsilon Squared: .0874 
Figure (4): The Friedman Test Statistics 
for Homogeneity for Systematic Review. 
Figure (5): The Friedman Test Statistics for 
Homogeneity for Clinical Trials 
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Figure (6): Meta-Analysis and Forest Plot  
 
 
 
 
 
 
 
 
 
Figure (7): Meta-Analysis and Forest Plot  (4 Weeks Timeline Evaluation) 
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